



**HAL**  
open science

## **Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid Cancer Risk: A Pooled Analysis of Two Case–Control Studies**

Monia Zidane, Thérèse Truong, Fabienne Lesueur, Constance Xhaard, Emilie Cordina-Duverger, Anne Boland, Hélène Blanché, Catherine Ory, Sylvie Chevillard, Jean-François Deleuze, et al.

### ► To cite this version:

Monia Zidane, Thérèse Truong, Fabienne Lesueur, Constance Xhaard, Emilie Cordina-Duverger, et al.. Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid Cancer Risk: A Pooled Analysis of Two Case–Control Studies. *Cancer Epidemiology, Biomarkers and Prevention*, 2021, 30 (6), pp.1208-1217. 10.1158/1055-9965.EPI-20-1142 . hal-03378112

**HAL Id: hal-03378112**

**<https://hal.univ-lorraine.fr/hal-03378112>**

Submitted on 14 Oct 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Role of DNA repair variants and diagnostic radiology exams in differentiated thyroid  
2 cancer risk: a pooled analysis of two case-control studies

3  
4 Monia, Zidane<sup>1,2,3</sup>, Thérèse, Truong<sup>1,2,3</sup>, Fabienne, Lesueur<sup>4</sup>, Constance, Xhaard<sup>5,6</sup>,  
5 Emilie, Cordina-Duverger<sup>1,2,3</sup>, Anne, Boland<sup>7</sup>, Hélène, Blanché<sup>8,9</sup>, Catherine, Ory<sup>10</sup>,  
6 Sylvie, Chevillard<sup>10</sup>, Jean-François, Deleuze<sup>7,8,9</sup>, Vincent, Souchard<sup>1,2,3</sup>, Yan, Ren<sup>1,2,3</sup>,  
7 Mohammed, Zakarya, Zemmache<sup>1,2,3</sup>, Sandra, Canale<sup>2</sup>, Françoise, Borson-Chazot<sup>11</sup>,  
8 Claire, Schvartz<sup>12</sup>, Eugènia, Mariné, Barjoan<sup>13</sup>, Anne-Valérie, Guizard<sup>14,15</sup>, Pierre,  
9 Laurent-Puig<sup>16</sup>, Claire, Mulot<sup>16</sup>, Julie, Guibon<sup>1,2,3,4</sup>, Mojgan, Karimi<sup>1,2,3</sup>, Martin,  
10 Schlumberger<sup>2,3</sup>, Elizabeth, Adjadj<sup>1</sup>, Carole, Rubino<sup>1,2,3</sup>, Pascal, Guenel<sup>1,2,3</sup>, Jean-  
11 Baptiste, Cazier<sup>17</sup>, Florent, de Vathaire<sup>1,2,3</sup>

- 12 1) INSERM, Centre for Research in Epidemiology and Population Health (CESP),  
13 94800 Villejuif, France
- 14 2) Université Paris-Sud Orsay, 94800 Villejuif, France
- 15 3) Gustave Roussy, 94800 Villejuif, France
- 16 4) Inserm, U900, Institut Curie, Université PSL, Mines ParisTech, Paris, France
- 17 5) INSERM Centre d'Investigation Clinique CIC-P 1433, CHRU Nancy, France
- 18 6) INSERM U1116, FCRIN INI-CRCT, Lorraine Université, Nancy, France
- 19 7) Université Paris-Saclay, CEA, Centre National de Recherche en Génomique  
20 Humaine, 91057, Evry, France
- 21 8) Fondation Jean Dausset-CEPH (Centre Etude du Polymorphisme Humain), Paris,  
22 France
- 23 9) Laboratory of Excellence GENMED (Medical Genomics)

24 10) CEA, Direction de la Recherche Fondamentale, Institut de Biologie François  
25 Jacob, iRCM, SREIT, Laboratoire de Cancérologie Expérimentale (LCE), Université  
26 Paris-Saclay, 92265, Fontenay-aux-Roses, France

27 11) Rhône-Alpes Thyroid Cancer Registry, Cancer Research Center of Lyon (UMR  
28 INSERM 1052, CNRS 5286), RTH Laennec Faculty of Medicine, University of Lyon,  
29 Lyon,

30 12) Thyroid Cancer Registry of Champagne-Ardennes, Institut Jean Godinot, Reims,  
31 Cancer Registry of Isère, Meylan,

32 13) Public Health Department, University Hospital Nice, Nice,

33 14) Registre Général des Tumeurs du Calvados, Centre François Baclesse, Caen,  
34 France

35 15) U1086 INSERM-UCN "ANTICIPE", Caen, France

36 16) Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC,  
37 Université Paris Descartes, Université Paris Diderot, EPIGENETEC, Paris, France

38 17) Institute of Cancer and Genomic Sciences, Centre for Computational Biology,  
39 University of Birmingham, Birmingham, B15 2TT, UK.

40 [moniazidane@gmail.com](mailto:moniazidane@gmail.com), [therese.truong@inserm.fr](mailto:therese.truong@inserm.fr), [fabienne.lesueur@curie.fr](mailto:fabienne.lesueur@curie.fr),

41 [c.xhaard@chru-nancy.fr](mailto:c.xhaard@chru-nancy.fr), [emilie.cordina@inserm.fr](mailto:emilie.cordina@inserm.fr), [boland@cng.fr](mailto:boland@cng.fr), [42 \[ceph.org\]\(http://ceph.org\), \[catherine.ory@cea.fr\]\(mailto:catherine.ory@cea.fr\), \[sylvie.chevillard@cea.fr\]\(mailto:sylvie.chevillard@cea.fr\), \[deleuze@cng.fr\]\(mailto:deleuze@cng.fr\),](mailto:helene.blanche@fjd-</a></p></div><div data-bbox=)

43 [vincent.souchard@gustaverouss.fr](mailto:vincent.souchard@gustaverouss.fr), [renyan0472@hotmail.com](mailto:renyan0472@hotmail.com),

44 [zemmache.zakarya@gmail.com](mailto:zemmache.zakarya@gmail.com), [sandra.canale@gustaveroussy.fr](mailto:sandra.canale@gustaveroussy.fr), [45 \[chazot@chu-lyon.fr\]\(mailto:chazot@chu-lyon.fr\), \[claire.schvartz@reims.unicancer.fr\]\(mailto:claire.schvartz@reims.unicancer.fr\), \[marine-barjoan.e@chu-nice.fr\]\(mailto:marine-barjoan.e@chu-nice.fr\),](mailto:francoise.borson-</a></p></div><div data-bbox=)

46 [av.guizard@baclesse.fr](mailto:av.guizard@baclesse.fr), [pierre.laurent-puig@parisdescartes.fr](mailto:pierre.laurent-puig@parisdescartes.fr), [claire.mulot@inserm.fr](mailto:claire.mulot@inserm.fr),

47 [julie.guibon@inserm.fr](mailto:julie.guibon@inserm.fr), [mojgan.karimi@inserm.fr](mailto:mojgan.karimi@inserm.fr),

48 [martin.schlumberger@gustaveroussy.fr](mailto:martin.schlumberger@gustaveroussy.fr), [elisabeth.adjadj@inserm.fr](mailto:elisabeth.adjadj@inserm.fr),

49 [carole.rubino@gustaveroussy.fr](mailto:carole.rubino@gustaveroussy.fr), [pascal.guenel@inserm.fr](mailto:pascal.guenel@inserm.fr), [j.cazier@bham.ac.uk](mailto:j.cazier@bham.ac.uk),

50 [florent.devathaire@gustaveroussy.fr](mailto:florent.devathaire@gustaveroussy.fr)

51 Running title: Role of DNA repair variants in thyroid cancer

52 Keywords: thyroid cancer genetics, thyroid epidemiology, ionizing radiations, DNA repair,  
53 cancer susceptibility

54 Corresponding author: Dr. Florent de Vathaire, mailing address: Radiation Epidemiology  
55 Group Unit1018INSERM Bâtiment B2M Institut Gustave Roussy 39, rue Camille  
56 Desmoulins 94805 Villejuif cedex Phone number: +33142115457, Fax number:  
57 +33142115315, Mobile: +33688093185, email address:  
58 [florent.devathaire@gustaveroussy.fr](mailto:florent.devathaire@gustaveroussy.fr)

59 The authors declare no potential conflicts of interest

60 **Abstract**

61 **Background:** Given the increased use and diversity of diagnostic procedures, it is  
62 important to understand genetic susceptibility to radiation-induced thyroid cancer.

63 **Methods:** Based on self-declared diagnostic radiology examination records in addition to  
64 existing literature, we estimated the radiation dose delivered to the thyroid gland from  
65 diagnostic procedures during childhood and adulthood in two case-control studies  
66 conducted in France. A total of 1071 differentiated thyroid cancer (DTC) cases and 1188  
67 controls from the combined studies were genotyped using a custom-made Illumina  
68 OncoArray DNA chip. We focused our analysis on variants in genes involved in DNA  
69 damage response and repair pathways, representing a total of 5817 single-nucleotide  
70 polymorphisms in 571 genes. We estimated the odds ratio per milli-Gray (OR/mGy) of the  
71 radiation dose delivered to the thyroid gland using conditional logistic regression. We  
72 then used an unconditional logistic regression model to assess the association between  
73 DNA repair gene variants and DTC risk. We performed a meta-analysis of the two  
74 studies. **Results:** The OR/mGy was 1.02 (95% CI: 1.00, 1.03). We found significant  
75 associations between DTC and rs7164173 in CHD2 ( $p = 5.79 \times 10^{-5}$ ), rs6067822 in  
76 NFATc2 ( $p = 9.26 \times 10^{-5}$ ), rs1059394 and rs699517 both in ENOSF1/THYS, rs12702628 in  
77 RPA3, and an interaction between rs7068306 in MGMT and thyroid radiation doses ( $p =$   
78  $3.40 \times 10^{-4}$ ). **Conclusions:** Our results suggest a role for variants in CDH2, NFATc2,  
79 ENOSF1/THYS, RPA3 and MGMT in DTC risk.

80 **Impact:** CDH2, NFATc2, ENOSF1/THYS and RPA3 have not previously been shown to  
81 be associated with DTC risk.

82 .

## 83 1. Introduction

84 Differentiated thyroid cancer (DTC) is the most common cancer of the endocrine system  
85 (1). The registered incidence of DTC has recently been increasing, especially in  
86 developed countries mostly due to increased screening (2). Exposure to thyroid ionizing  
87 radiation (IR) during childhood was the first risk factor linked with DTC, an association  
88 that has been well characterized over several decades (3–8).

89 In a pooled study performed on doses higher than  $\geq 1$  Gy (9,10), the excess of DTC  
90 relative risk per Gray (ERR/Gy) delivered to the thyroid gland during childhood ranged  
91 between 5 and 10. When restricting the pooled analysis to doses lower than 0.2 Gy,  
92 however, the ERR/Gy was slightly higher (11). A higher magnitude of excess risk for low  
93 dose exposure during childhood was also observed in a cohort study of Japanese atomic  
94 bomb survivors (12). Nevertheless, some uncertainties remain about how the recent  
95 increase in the use of diagnostic procedures involving irradiation, such as CT  
96 (computerized tomography), might affect DTC incidence (13,14).

97 Despite being more subject to recall bias than cohort studies, case-control studies may  
98 be more helpful for improving understanding of thyroid low-dose radiation risk since case-  
99 control studies utilize a high number of cases and permit a more detailed investigation of  
100 a high number of potential risk cofactors, which are costlier to investigate in cohort  
101 studies. Since DTC risk after low radiation dose exposure is also likely modulated by  
102 individual susceptibility, investigating the association between DNA variants and DTC risk  
103 after low radiation dose could also facilitate an improved understanding of this risk. IR  
104 exposure causes DNA damage as well as other physical and chemical biomolecule  
105 alterations. DNA double-strand breaks (DSBs) are a characteristic cellular response to IR  
106 exposure (15). Exposure to low-dose IR (from levels 50mGy and lower) from X-ray

107 examinations has been demonstrated to increase the risk of chromosomal translocation  
108 (16), suggesting the possibility of long-term adverse health effects.

109 DSBs trigger the DNA repair system, but the effect of these DSBs varies with cumulative  
110 exposures and individual susceptibility. To our knowledge, only one published study has  
111 investigated an interaction between genetic background and the radiation-related DTC  
112 risk after diagnostic radiation exposure (17). This study identified 24 single-nucleotide  
113 polymorphisms (SNPs) with a p-value of variant-RI doses interaction was  $< 0.05$  for all  
114 types of DTC cases (papillary and follicular). Currently, few genes including *FOXE1*,  
115 *ATM*, and *LIG1* have been associated with DTC risk after IR exposure, but most  
116 published studies of these genes were conducted in highly irradiated populations.  
117 Moreover, these identified genes were associated with sporadic DTC (18).

118 Given the increasing use of diagnostic radiology exams and the proliferation of radiology  
119 procedure types, it is important to explore the side effects of multiple low-radiation  
120 exposures, such as potential effects on DTC development, especially for patients  
121 exposed at a young age.

122 In the current study, we investigated the association between diagnostic low-dose IR  
123 exposures and DTC risk. We quantified the doses delivered to the thyroid gland during  
124 childhood and adulthood in two French case-control studies. We also investigated the  
125 role of genetic variants located in 604 DNA damage signaling and repair genes in  
126 modifying the effect of exposure to diagnostic procedure radiation on DTC risk.

## 127 2. Materials and methods

### 128 2.1. Case-control studies

129 Our study included cases and controls from two studies conducted in distinct regions  
130 from metropolitan France.

131 The CATHY study (19) was a case-control study conducted in Marne, Ardennes, and  
132 Calvados, three French administrative areas covered by a cancer registry. Eligible cases  
133 were all DTC patients aged 25 years and older that were diagnosed between 2002 and  
134 2007 and resided in these areas. Controls were recruited by selecting and contacting  
135 telephone numbers at random, then frequency-matching the individuals to patients by sex  
136 and five-year age groups; controls were randomly selected among healthy individuals  
137 residing in the same study areas at the time of the matched cases diagnoses. From the  
138 621 cases and 706 controls initially included in the CATHY study, saliva DNA samples  
139 (Oragene® DNA testing kit) were available for 583 cases and 643 controls.

140 The Young-Thyr study (20) is a case-control study conducted in eastern regions of  
141 France: Alsace, Champagne-Ardennes, Corse, Franche-Comté, Lorraine, Rhône-Alpes,  
142 and Provence-Alpes-Côte d'Azur. Eligible cases were all DTC patients diagnosed with  
143 DTC between January 1st, 2002, and December 31<sup>st</sup>, 2006 that were younger than 35  
144 years of age with their main residence in a region of eastern France. Controls were  
145 selected from the general population and individually matched to a single patient of the  
146 same sex, year of birth (within one year), and region of residence during the year when  
147 the patient was diagnosed with cancer. From the 805 cases and the 876 controls  
148 included in the Young-Thyr study, DNA from saliva (Oragene®) was available for 715  
149 cases and 692 controls.

150 Participants from both studies answered similar questionnaires that were collaboratively  
151 developed. Information on a personal and familial history of thyroid disease, hormonal  
152 and reproductive factors, weight, height, dietary habits, tobacco smoking, and medical  
153 history was collected during in-person interviews. Participants from both studies gave  
154 their informed written consent before being interviewed by trained interviewers. Both



155 studies were approved by the Ethics Committee and the French National Commission for  
156 Data Protection (CNIL).

157 Clinical and epidemiological data from both studies were harmonized and aggregated in  
158 one database. During this process, 30 subjects were excluded because they were  
159 duplicates in the two studies.

## 160 [2.2. Radiologic procedure history](#)

161 In the questionnaire, participants were asked to report their history of diagnostic radiology  
162 examinations by providing the year and the reason for each examination. The exams  
163 considered were conventional radiography, CT scans, and nuclear medicine.  
164 Examinations linked to investigating thyroid pathology were excluded and were not  
165 considered in the dose estimation or any analysis. Examinations carried out during  
166 childhood (before the age of 20 years) and adulthood (over 20 years) were analyzed  
167 separately. All procedures reported by participants were classified by period (before  
168 1980, 1980-1989, 1990, and after) to take into account the development of radiologic  
169 procedure technology over this time.

## 170 [2.3. Thyroid radiation dose estimates](#)

171 To estimate the absorbed radiation doses administered to the thyroid gland for different  
172 types of diagnostic radiology examinations, we reviewed papers published up to July  
173 2018 that included absorbed dose estimates to the thyroid. From 1970 to 2002, only one  
174 study provided estimates of absorbed doses to organs, including the thyroid gland (21),  
175 and was used to calculate dose estimates from conventional radiography.

176 If sex-specific data were available, a mean dose was used. Since the available data  
177 about childhood exams were very limited, specific doses were available only for children  
178 under the age of two years old without consideration of the period of exposure. Children

179 older than two years were assumed to receive the same doses as adults. All doses per  
180 exam that were equal to or less than 0.01 mGy were considered to be null because of the  
181 magnitude of daily natural irradiation in France. Table 1 summarizes the different values  
182 used per diagnostic procedure type (conventional radiography, CT scan, nuclear  
183 medicine), per period (before 1980, 1980-1989, 1990 and after), and per age at  
184 examination ( $\leq 2$  years old,  $> 2$  years).

#### 185 2.4. Genotyping and quality control

186 DNA was extracted from saliva samples using a semi-automated salt precipitation  
187 method. All subjects were genotyped using the Infinium OncoArray-500K BeadChip  
188 (Illumina). This array has been previously described in detail (22) and contains 499,170  
189 SNPs. We incorporated 13,759 additional custom markers based on prior evidence of  
190 association in genes involved in relevant biological pathways, such as thyroid function.

191 The quality control process was applied to the data of each study separately. A threshold  
192 of 5% was applied for a missing call rate per SNP and individual. The Hardy-Weinberg  
193 equilibrium (HWE) was also assessed per SNP among controls, using an exact test with  
194 a p-value threshold at  $10^{-5}$ . Only SNPs with a minor allele frequency (MAF) above 5%  
195 were included in the analyses.

196 The FastPop R package was used to infer intercontinental ancestry with a principal  
197 component-derived method (23). Only individuals identified as European were kept in the  
198 genetic analyses. A total of 443 cases and 532 controls from CATHY and 629 cases and  
199 656 controls from Young-Thyr were included in the analysis of SNPs.

200 SNPs of DNA damage signaling and repair genes according to the Gene Ontology  
201 database (24,25) were examined. We initially selected exonic and intronic variants in 604

202 genes. After the quality control steps, a total of 5817 SNPs in 571 genes were retained  
203 for the analysis (all genes are listed in the Supplementary Table S1).

## 204 2.5. Statistical methods

205 We used a conditional logistic regression model to estimate the odds ratio of DTC per  
206 mGy (OR/mGy) of radiation dose received by the thyroid gland. Because in our study,  
207 thyroid doses were very low and cell killing not likely to play significance, and because  
208 our goal was not to define the best model for thyroid cancer risk after low dose but rather  
209 the best model to investigate the interaction between thyroid radiation and genetic  
210 factors, we only investigate models with one parameter for the thyroid radiation dose. In  
211 this way, we compared a linear model ( $OR=Cst (1 + \alpha \text{ dose})$ ) to a “constant” model  
212 without a radiation dose ( $OR= Cst$ ) and other models with one parameter, such as  
213 quadratic ( $OR=1 + \alpha \text{ dose}^2$ ) and exponential ( $OR=1 + e (\alpha \text{ dose})$ ), rather to traditional  
214 dose-response models used in radiation epidemiology (26). These comparisons were  
215 done using Akaike Information Criterion (AIC) (27). Similarly, we investigated the  
216 potential role of a dose-response modifier by introducing a term for interaction in the  
217 models. The analysis of the radiation dose was performed by using the PECAN module  
218 of Epiwin® software. To assess the association between SNPs and DTC risk, odds ratios  
219 (ORs) and 95% confidence intervals (95% CIs) were derived from unconditional logistic  
220 regression models, assuming a log-additive model since the stratum was not considered  
221 in this step. Analyses were first conducted in the Young-Thyr study to filter our SNPs and  
222 limit the number of tests to be performed later; only the 100 SNPs with the lowest p-  
223 values from this step were tested in the CATHY study. We also conducted a meta-  
224 analysis combining results from both studies; overall z-statistics and p-value for these  
225 100 top SNPs were then calculated from a weighted sum of the individual statistics.  
226 Weights were proportional to the square root of the number of individuals examined in

227 each sample and selected such that the squared weights summed to 1.0, as  
228 implemented in the METAL program (28). This step aims to improve signal detection in  
229 the genetic analysis by avoiding a large number of tests, and to substantiate homologous  
230 signals in both studies since our population is relatively limited.

231 To correct for multiple tests in the main effect analysis, the FDR procedure (29) was  
232 calculated for each result of the meta-analysis. We investigated the interaction between  
233 SNPs and radiation doses using the likelihood ratio test, comparing models with and  
234 without the interaction term following the same steps described above.

235 All analyses were adjusted for age (five-year period), sex, thyroid cancer family history  
236 (yes/no), goiter history (yes/no), radiotherapy history (yes/no), BMI (continuous), height  
237 (continuous), educational level (primary school, secondary school, bachelors or higher),  
238 smoking status (never/former smoker/smoker), number of pregnancies longer than seven  
239 months in women (three classes), and study (CATHY/Young-Thyr) only in the pooled  
240 analysis. Analyses of genetic variants were additionally adjusted for the first three  
241 principal components to take into account the population stratification. Subgroup analysis  
242 was also performed separately for papillary histological type cases and according to  
243 tumor size (microcarcinoma and macrocarcinoma).

244 The log-linear model poses fewer convergence problems than the linear model, for that  
245 reason the association and interaction tests between radiation doses and DNA variants  
246 were performed using a log-linear model. Since we did not apply any cut-off p-values for  
247 SNPs selected to be included in the meta-analysis step, in this study we chose to only  
248 show our best five results from each analysis.

249 Association analyses and meta-analyses were performed using R 3.6 and METAL (28).  
250 SNPs were annotated using the VEP tool (30), and gene regions were plotted with  
251 LocusZoom software (31).

### 252 3. Results

253 Demographic characteristics of the pooled study population (Young-Thyr and CATHY)  
254 are described in Table 2. More than 75% of our population were women and non-  
255 smokers. Papillary thyroid cancer type was the most frequent type of thyroid cancer  
256 observed, with a mean age at diagnosis younger than 40 years old. However, the mean  
257 age at diagnosis was lower in the Young-Thyr study than in the CATHY study, as shown  
258 in Supplementary Table S2 (27 years *versus* 51 years).

#### 259 3.1. Diagnostic radiation and thyroid cancer risk

##### 260 3.1.1. Thyroid doses determined by diagnostic radiology examination estimates

261 Estimated IR doses administered to the thyroid during childhood were lower than those  
262 given after 20 years of age. Among children, the most frequent exam was panoramic  
263 dental radiography, which was reported in 971 individuals. Nuclear medicine exams were  
264 rarely reported among children; the most frequent exam scan was bone scans reported in  
265 14 children (Table 3). During adulthood, the most frequent conventional radiography  
266 exam was chest radiography, which was seen in 30.8% of adults. Skull CT scan was the  
267 most common computed tomography exam during adulthood. Nuclear medicine exams  
268 were also relatively rarely reported among adults (Table 3). The median thyroid doses  
269 delivered during childhood were lower than doses administered during adulthood. The  
270 maximum childhood estimated thyroid dose was 194.2 mGy among the whole population,  
271 the mean among cases was 2.8 mGy and 2.0 mGy among controls. A total of 1672  
272 subjects reported not having received any thyroid-irradiating diagnostic procedure during  
273 childhood. The estimated maximum dose delivered to the thyroid during adulthood in a

274 diagnostic radiology procedure was 260.0 mGy, and the mean dose was 5.6 mGy and  
275 5.5 mGy among cases and controls, respectively (Supplementary Tables S3 and S4). A  
276 total of 1466 subjects did not report experiencing any thyroid-irradiating diagnostic  
277 procedures during adulthood. Detailed information on diagnostic radiology exams and  
278 thyroid doses in cases and controls in each study are shown in Supplementary Tables  
279 S2, S3, and S4. Characteristics and thyroid doses among genotyped subgroups from  
280 both studies are presented in Table 2. The DTC risk in relation to the radiation doses in  
281 this population is detailed in Supplementary Table S5.

### 282 3.1.2. Differentiated thyroid cancer risk in relation to thyroid radiation doses

283 Only estimated radiation dose received by the thyroid gland during childhood was found  
284 to be associated with an increased DTC risk, unlike doses received during adulthood. In  
285 the linear model, the DTC OR per mGy administered to the thyroid was equal to 1.02  
286 (95% CI: 1.00, 1.03). When restricting the analysis to papillary thyroid carcinoma, the OR  
287 per mGy was very similar. The fit of the model was improved by the addition of a  
288 quadratic term to take into account a possible higher effect of high doses, although not  
289 significant ( $p = 0.06$ ). No significant difference ( $p > 0.05$ ) was found between the dose  
290 responses for men and for women. No interaction was apparent between the thyroid  
291 radiation dose and obese status, age at DTC occurrence, study, number of pregnancies,  
292 female sex, smoking status, height, or the personal radiotherapy history. In a log-linear  
293 model, the odds ratio for a dose of 1 mGy was 1.01 (95% CI: 1.01, 1.04) (Table 4).  
294 Results from a sub-analysis by tumor size, shown in Table 4, yielded similar DTC risk in  
295 relation to thyroid IR doses to these from the whole population analysis.

### 296 3.2. Differentiated thyroid cancer risk in relation to DNA damage repair and signaling 297 gene variants

298 Association analysis between DTC risk and the 5817 variants in DNA damage response  
299 genes from the Young-Thyr study including all histological types yielded only two SNPs  
300 with a p-value lower than  $5 \times 10^{-4}$ : rs4962347 (chromosome 10, *C10orf90*) and  
301 rs16983787 (chromosome 10, *SMC6*). None of the top 100 variants with the lowest p-  
302 values reached the threshold p-value of  $5 \times 10^{-4}$  in the CATHY study. In the meta-analysis,  
303 results of the association test with DTC risk showed a significantly reduced risk for  
304 carriers of the minor allele [T]; both SNPs, rs6067822 in *NFATc2* and rs7164173 in  
305 *CHD2*, had a p-value of  $5.79 \times 10^{-5}$  and  $9.26 \times 10^{-5}$  respectively, under an additive model of  
306 inheritance. Associations with both variants were in the same direction in CATHY and  
307 Young-Thyr (Table 5A). Other variants in *NFATc2* present among the top 100 SNPs  
308 associated with DTC in the Young-Thyr study are described in Supplementary Figure 1.  
309 Rs7164173 was the only SNP in *CHD2* among the top 100 SNPs. Rs105939 and  
310 rs699517 in *ENOSF1/THYS* were in our best results, but statistical significance was not  
311 achieved ( $OR_{\text{meta-analysis}} = 1.30$ ,  $p\text{-value}_{\text{meta-analysis}} = 7.81 \times 10^{-4}$ ). Only one variant in RPA3  
312 (rs12702628 in 7p21.3) was found to be significantly associated with DTC risk.

313 When the analysis was restricted to only papillary carcinoma histological types, only  
314 rs7164173 was significant ( $p\text{-value}_{\text{meta-analysis}} = 9.33 \times 10^{-5}$ ) (Table 5B). In the *NFATc2*  
315 region, two SNPs, rs77971457 and rs6067822, had respective  $OR_{\text{meta-analysis}}$  values of  
316 1.45 and 0.77 but did not reach the significance threshold. Rs1290997 and rs1950764 in  
317 *RAD51B* had  $OR_{\text{meta-analysis}}$  values of 0.74 and 0.60, respectively (Table 5B). The  
318 polymorphism rs1950764 had a  $p\text{-value}_{\text{meta-analysis}} > 5 \times 10^{-4}$ . Detailed results for SNPs in  
319 *RAD51B* are shown in Supplementary Figure 2. Results from the best SNPs in the  
320 macrocarcinoma analysis (Table 5C) yielded two SNPs in the *MLK7-AS1* gene



321 (rs72625242, rs16861406) in 2q31.1 in addition to two other SNPs in chromosome 2  
322 (*PMSD1* and *SMC6*) and the *C10orf90* gene in chromosome 10. In the microcarcinoma  
323 analysis, a significant result in 2q31.1 was found (rs75361806, *TLK1*) (Table 5D). The  
324 best results from this later analysis also yielded three SNPs in the *MACROD2* gene  
325 (20p12.1).

### 326 3.3. Differentiated thyroid cancer risk related to the interaction between thyroid doses 327 and variants of DNA damage repair and signaling genes

328 We investigated the interaction between variants in DNA damage response genes and  
329 thyroid exposure to radiation in DTC risk. In the meta-analysis, the SNP-radiation  
330 interaction term yielded a p-value<sub>meta-analysis</sub> =  $3.4 \times 10^{-4}$  and an OR<sub>interaction</sub> = 0.65 for  
331 rs7068306 in *MGMT* (Table 6). A second *MGMT* SNP, rs7087131, was also among the  
332 top 100 SNPs identified in the Young-Thyr study. Results on the modifying effect of  
333 rs7068306 genotypes on DTC risk according to diagnostic radiation exposure study  
334 separately in CATHY and Young-Thyr are presented in Supplementary Table S6.

## 335 4. Discussion

336 Our main objective was to investigate the potential genetic susceptibility to DTC after  
337 exposure to low IR doses from diagnostic procedures performed during childhood. In our  
338 study, the estimated OR/mGy for thyroid radiation doses received during childhood  
339 (OR/mGy = 1.02 (95% CI: 1.00, 1.03)) was similar to the OR/mGy values of the pooled  
340 DTC study by Veiga et al. (10) when considering analyses restricted to thyroid radiation  
341 doses lower than 100 mGy (OR/mGy = 1.010, (95% CI: 1.004 - 1.018)) or to thyroid  
342 radiation doses lower than 200 mGy (OR/mGy = 1.011, (95% CI: 1.007 - 1.02)) (11).  
343 Compared to the latest publication on the US radiologic technologist cohort, including  
344 90,305 radiologic technologists in the U.S. who were followed during 1983–1998, the  
345 values of our coefficients for thyroid radiation doses received during childhood are slightly



346 higher than the coefficients estimated in the general analysis and the papillary carcinoma  
347 sub-analysis (32). Our estimates are also slightly higher than estimates in both the most  
348 recent analysis among Japanese atomic-bomb survivors(12) and the IARC study of the  
349 highly contaminated area of Belarus following the Chernobyl nuclear accident (8).

350 The genetic analyses showed an association between DTC risk and SNPs: rs6067822 in  
351 intron 1 of *NFATc2* (20q11.22), rs7164173 in intron 3 of *CHD2* (15q21.3), rs1059394 (3  
352 prime UTR variant), and rs699517 (3 prime UTR variant) both in *ENOSF1/THYS*  
353 (18p11.32), and rs12702628 intron variant in *RPA3* (7p21.3). To our knowledge, none of  
354 these genes have previously been reported to be associated with DTC risk. The effect  
355 direction of these SNPs was similar in the Young-Thyr and CATHY studies and reached  
356 the significance threshold for the meta-analysis; furthermore, *NFATc2* and *CHD2* genes  
357 have been implicated in the response to ionizing and ultraviolet radiation *in vitro* studies  
358 (33,34). Moreover, cells with mutations in *CHD2* were found to be defective in their ability  
359 to repair DNA damage, especially after ionizing and ultraviolet radiation exposure (34).  
360 Genes of the *NFAT* family encode for transcription factors, which have a role in cancer  
361 progression, and also are important for responding to ionizing and ultraviolet radiation  
362 exposure (35–37); these genes were previously found to be associated with other types  
363 of cancer risk, such as melanoma, breast, colorectal and oral cancers (38–41).  
364 Rs6067822 in *NFATc2* and rs7164173 in *CHD2* showed a similar stabilizing effect in  
365 general and papillary subgroup analyses. Our results from the papillary thyroid carcinoma  
366 sub-analysis yielded a significant association of rs1290997 in *RAD51B* with DTC risk.  
367 Another variant in this gene, rs1950764, was among our top five SNPs but did not reach  
368 the significance threshold. These findings suggest a role for *RAD51B* in the etiology of  
369 radiation-related DTC. Interestingly, the *RAD51B* gene was involved in DNA damage  
370 repair after ultraviolet irradiation exposure (42,43) and associated with breast cancer risk

371 (44,45). We report this result with great caution because 525 SNPs in this gene were  
372 tested in the first step of the analysis (Supplementary Table S1).

373 An association was found between two SNPs (rs1059394 and rs699517) falling within the  
374 *ENOSF1/THYS* gene region. These SNPs are non-coding transcript exon variants, and  
375 this region is known to be associated with ovarian and endometrial cancers (46,47).

376 The polymorphism rs12702628 in replication protein A3 gene (*RPA3*), which was  
377 associated with DTC risk in our study, has previously been found to be involved in  
378 tumorigenesis, especially in gastric cancer (48).

379 The macrocarcinoma and microcarcinoma analyses both yielded significant results in  
380 2q31.1. However, since these are subgroups results, they should be taken with caution,  
381 especially for the microcarcinoma analysis due to the low number of cases.

382 The minor allele of *MGMT* rs7068306 was found to interact with thyroid IR doses during  
383 childhood in reducing the risk of DTC after exposure. The first study to report an  
384 association between an *MGMT* variant and radiation-related DTC risk was performed in  
385 Belarusian children exposed to radiation (49). The polymorphism rs2296675, associated  
386 with DTC risk in the Belarusian population, is located 94 kb from rs7068306 in intron 4 of  
387 the *MGMT* region. A correlation coefficient of  $r^2 = 0.005$  was found between rs7068306  
388 and rs2296675. In a study of a Caucasian population, Sandler et al. found an interaction  
389 between other *MGMT* variants: rs1762444, rs4750763, and rs12219606, and exposure to  
390 radiation from diagnostic procedures (17). These SNPs are located in intron 2 and are  
391 244kb, 26kb, and 15kb from rs7068306, respectively. The  $r^2$  values between these three  
392 SNPs and rs7068306 are 0.009 and 0.044 (Supplementary Table S7). The  $r^2$  values  
393 between rs7068306 and the SNPs tested in studies by Lonjou and Sandler were  
394 estimated in a European reference population of 1000 Genomes project (50). Results

395 from the present study were obtained after estimation and quantification of thyroid doses,  
396 based on a combination of self-reported radiologic procedure history and literature doses  
397 separately on childhood and adulthood observations. The Sandler et al. study used a  
398 different procedure since no doses were taken into account; only categories of diagnostic  
399 procedure exposure based on self-reported history were evaluated. Taken together,  
400 results from these different studies highlight the role of *MGMT* in modulating the effect of  
401 IR on cells of the thyroid.

402 The expression of *CLIP2*, a gene located on 7q11.22, has been found to be strongly  
403 linked with previous radiation exposure in thyroid cancer (51). In our study, only 22 SNPs  
404 located on chromosome 7 were tested (Supplementary Table S1), of which, only two  
405 were near the *CLIP2* gene region. None of these were among the 100 best SNPs in our  
406 study, since the low numbers of concerned SNPs prevented us from confirming any  
407 results about locus 7q11.22.

#### 408 **Limitations of the study**

409 Investigating the thyroid radiation dose-response from self-reported radiation  
410 examinations carried out in case-control studies is sensitive to recall bias. This is  
411 particularly true when addressing public health issues highly debated by the public, such  
412 as the health effects of irradiation. As Hallquist and Jansson previously showed, in case-  
413 control studies investigating the impact of self-reported diagnostic radiology procedures  
414 on DTC risk, this bias produces under-reporting of examinations by both cases and  
415 controls, but significantly more by controls; furthermore, this bias could cause an  
416 overestimate of the IR effect (52). We cannot exclude such a bias in our study, which  
417 could result in an overestimation of the radiation dose effect. However, in the Young-Thyr  
418 study, we previously showed that despite DTC patients being more likely than controls to  
419 believe that the consequences of the Chernobyl accident were responsible for DTC

420 occurrences, self-reported vegetable consumption during the two months after the  
421 Chernobyl accident, known to be a major source of radioactive contamination, was  
422 correlated with the status of participants, cases or controls, but not with their beliefs (53).  
423 Thus, exposure could be over-reported in patients, particularly when they believe that this  
424 exposure contributed to their disease. In this type of study, case and control self-  
425 declarations are often impacted by recall bias, especially in terms of the number of radio  
426 diagnostic exams and images in the present study. Despite these caveats, case-control  
427 studies could help to improve understanding of the risks associated with low-dose IR  
428 radiation by utilizing a large number of cases and permitting more detailed investigations  
429 on several potential risk factors, which are costlier to investigate in cohort studies.

430 For some types of exams, there are no available thyroid dose estimates available in  
431 current literature, especially during childhood. This disadvantage could decrease the  
432 precision of our estimates; consequently, to harmonize our analyses we considered the  
433 same doses for all children older than 2 years. The simplest way to account for age  
434 variation of radiation dose exposure (0-2 years compared to older) in our analysis, has  
435 probably a limited effect because the reference doses were the same for cases and  
436 controls. Thyroid dose estimates were based on self-declarations of diagnostic exam  
437 history. In this data, dates for each exam are not precise, causing the impossibility to  
438 impose a lagging period and raising the problem of reverse causation. Despite the  
439 absence of specific dates for each procedure, we only kept data from radiological  
440 procedures that were not carried out for diagnosing thyroid cancer. There is some  
441 heterogeneity in demographic and cancer characteristics between our two studies:  
442 patients from the Young-Thyr study were younger at cancer diagnosis and inclusion in  
443 the study compared to cases from CATHY. Furthermore, diagnostic radiology  
444 technologies that were available in childhood differ substantially between the participants

445 of the CATHY and Young-Thyr studies; additionally, the availability and frequency of  
446 these examinations differ (Supplementary Tables S2, S3, and S4). To better discern  
447 signals from the genetic analysis and to increase the statistical power, we chose to  
448 perform a meta-analysis to substantiate homologous signals in both studies by keeping a  
449 limited number of SNPs in this step to avoid a high number of tests.

450 Despite the small size of our study populations, our results suggest a role for *NFATc2*,  
451 *CHD2*, *RPA3*, and *ENOSF1/THYS* that has not previously been associated with DTC risk  
452 and confirm the previously demonstrated role of *RAD51B* and *MGMT*. However,  
453 functional and validation studies are needed to better understand and confirm the  
454 biological role of these variants.

## 455 5. Conclusion

456 We present evidence that DTC risk is significantly increased in higher thyroid radiation  
457 doses received during childhood from radio diagnostic examinations. In addition, we  
458 demonstrated an interaction between this thyroid radiation dose and the minor allele of  
459 rs706830 located in *MGMT*. Our results also suggest an association between  
460 polymorphisms in *NFATc2*, *CHD2*, *ENOSF1/THYS*, *RPA3*, and *RAD51B*. Taken  
461 together, despite the limited size of both populations studied, these results underline the  
462 role of DNA repair pathways in DTC risk. More studies of larger populations are needed  
463 to validate and characterize the interaction between DNA repair genes and exposure to  
464 low IR doses.

## 465 Acknowledgement:

466 FDV received the following grants as principal investigator of Young-Thyr study: Fondation de  
467 France (Grant number 65391), L'Alliance pour les sciences de la vie et de la santé,  
468 « AVIESAN » (Grants number ENV201416 and 2007005070), the Ligue Nationale Contre le  
469 Cancer (LNCC) (Grants number EPDAC6036, EPDTP6004, R10127LL).

470 TT received the following grants for CATHY and Young-Thyr studies genotyping Institut  
471 National du Cancer (Grant number 9533), the ARC foundation (Grant number  
472 PGA120150202302)

473 MZ performed this work during her PhD funded by Ecole des Hautes Etudes en Santé  
474 Publique (EHESP) and the ARC Foundation (Grant number ARCD0C42020070002532).

475 The funders had no role in study design, data collection and analysis, decision to publish, or  
476 preparation of the manuscript.

477 We would like to thank the CEPH-Biobank team, Informatique et Statistique en Anatomie  
478 Pathologique en Provence-Alpes-Côte d'Azur (CRISAP PACA) team, as well as Dr C Sattonnet,  
479 Dr JL Lassalle, Dr Z Hafdi-Nejjari, Dr P Delafosse, Ms Kami-Marie Moreau, Ms Cyrielle Orenes,  
480 Ms Laurianne Sarrazin, Ms Stéphanie Bonnay, Ms Frédérique Chatelain, Ms Maryse Barouh, Ms  
481 Evelyne Rapp, Ms Julie Festraëts, Ms Julie Valbousquet, Mr Yusuf Atilgan, Mr Jean Chappellet,  
482 Ms Lallia Bedhouche, Mr Florent Dayet and Ms Ziyam Fami for their involvement in Young-Thyr  
483 study.

484

## 485 6. References

- 486 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* [Internet]. 2016  
487 [cited 2018 Feb 22];66:7–30. Available from: <http://doi.wiley.com/10.3322/caac.21332>
- 488 2. Vanderpump MP, Vanderpump MPJ. The epidemiology of thyroid disease. 2011 [cited  
489 2019 May 1]; Available from: <https://www.researchgate.net/publication/51619844>
- 490 3. Stepanenko VF, Voillequé PG, Gavrilin YI, Khrouch VT, Shinkarev SM, Orlov MY, et al.  
491 Estimating individual thyroid doses for a case-control study of childhood thyroid cancer in  
492 Bryansk Oblast, Russia. *Radiat Prot Dosimetry*. 2004;108:143–60.
- 493 4. Modan B, Ron E, Werner a. Thyroid cancer following scalp irradiation. *Radiology*  
494 [Internet]. 1977;123:741–4. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11550916>
- 495 5. Thomas GA, Bethel JA, Galpine A, Mathieson W, Krznaric M, Unger K. Integrating  
496 Research on Thyroid Cancer after Chernobyl - The Chernobyl Tissue Bank. *Clin Oncol*.  
497 2011;23:276–81.
- 498 6. Inskip PD, Sigurdson AJ, Veiga L, Bhatti P, Ronckers C, Rajaraman P, et al. Radiation-  
499 Related New Primary Solid Cancers in the Childhood Cancer Survivor Study: Comparative  
500 Radiation Dose Response and Modification of Treatment Effects. *Int J Radiat Oncol*

- 501 [Internet]. Elsevier; 2016 [cited 2018 Mar 9];94:800–7. Available from:  
502 /pmc/articles/PMC5011040/?report=abstract
- 503 7. Memon A, Godward S, Williams D, Siddique I, Al-Saleh K. Dental x-rays and the risk of  
504 thyroid cancer: A case-control study. *Acta Oncol (Madr)*. 2010;
- 505 8. Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, et al. Risk of  
506 thyroid cancer after exposure to 131I in childhood. *J Natl Cancer Inst*. 2005;
- 507 9. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, et al. Thyroid cancer after  
508 exposure to external radiation: A pooled analysis of seven studies. *Radiat Res* [Internet].  
509 1995 [cited 2018 Mar 9];141:259. Available from:  
510 <https://pdfs.semanticscholar.org/458b/269115db3599d129db1e5ea262797801ecf4.pdf>
- 511 10. Veiga LHSS, Lubin JH, Anderson H, De Vathaire F, Tucker M, Bhatti P, et al. A pooled  
512 analysis of thyroid cancer incidence following radiotherapy for childhood cancer. *Radiat*  
513 *Res* [Internet]. Radiation Research Society; 2012 [cited 2019 Jul 22];178:365–76. Available  
514 from: <http://www.bioone.org/doi/10.1667/RR2889.1>
- 515 11. Lubin JH, Adams MJ, Shore R, Holmberg E, Schneider AB, Hawkins MM, et al. Thyroid  
516 Cancer Following Childhood Low-Dose Radiation Exposure: A Pooled Analysis of Nine  
517 Cohorts. *J Clin Endocrinol Metab* [Internet]. Oxford University Press; 2017 [cited 2018 Feb  
518 2];102:2575–83. Available from: [https://watermark.silverchair.com/jc.2016-3529.pdf?token=AQECAHi208BE49Ooan9kKhW\\_Ercy7Dm3ZL\\_9Cf3qfKAc485ysgAAAcAwggG8BqkqhkiG9w0BBwagggGtMIIBqQIBADCCAaIGCSqGSIB3DQEHATAeBgIghkgBZQMEAS4wEQQMrRtJ0z4bOGsSwgHqAgEQgIIBc\\_k2gqTLY7sh-3b\\_MfRg1yTu7gaJNIXNvOJtfMUOc](https://watermark.silverchair.com/jc.2016-3529.pdf?token=AQECAHi208BE49Ooan9kKhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAcAwggG8BqkqhkiG9w0BBwagggGtMIIBqQIBADCCAaIGCSqGSIB3DQEHATAeBgIghkgBZQMEAS4wEQQMrRtJ0z4bOGsSwgHqAgEQgIIBc_k2gqTLY7sh-3b_MfRg1yTu7gaJNIXNvOJtfMUOc)
- 523 12. Furukawa K, Preston D, Funamoto S, Yonehara S, Ito M, Tokuoka S, et al. Long-term  
524 trend of thyroid cancer risk among Japanese atomic-bomb survivors: 60 years after  
525 exposure. *Int J Cancer* [Internet]. John Wiley & Sons, Ltd; 2013 [cited 2019 Feb  
526 27];132:1222–6. Available from: <http://doi.wiley.com/10.1002/ijc.27749>
- 527 13. Leung AM. Low-Dose Childhood Radiation Effects to the Thyroid Follow a Linear Dose–  
528 Response Trend and Persist Even 45+ Years After Exposure. *Clin Thyroidol* [Internet].  
529 2017 [cited 2018 Mar 9];29:235–6. Available from:  
530 <http://online.liebertpub.com/doi/10.1089/ct.2017%3B29.235-236>
- 531 14. Mazonakis M, Tzedakis A, Damilakis J, Gourtsoyiannis N. Thyroid dose from common  
532 head and neck CT examinations in children: is there an excess risk for thyroid cancer  
533 induction? *Eur Radiol* [Internet]. Springer-Verlag; 2007 [cited 2018 Mar 9];17:1352–7.



- 534 Available from: <http://link.springer.com/10.1007/s00330-006-0417-9>
- 535 15. Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-  
536 strand breaks by non-homologous end-joining. *Biochem J* [Internet]. Portland Press  
537 Limited; 2009 [cited 2018 Nov 8];417:639–50. Available from:  
538 <http://www.ncbi.nlm.nih.gov/pubmed/19133841>
- 539 16. Bhatti P, Yong LC, Doody MM, Preston DL, Kampa DM, Ramsey MJ, et al. Diagnostic X-  
540 ray examinations and increased chromosome translocations: evidence from three studies  
541 NIH Public Access. *Radiat Env Biophys*. 2010;49:685–92.
- 542 17. Sandler JE, Huang H, Zhao N, Wu W, Liu F, Ma S, et al. Germline Variants in DNA Repair  
543 Genes, Diagnostic Radiation, and Risk of Thyroid Cancer. *Cancer Epidemiol Biomarkers*  
544 *Prev* [Internet]. American Association for Cancer Research; 2018 [cited 2018 Mar  
545 9];27:285–94. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29263185>
- 546 18. Zidane M, Cazier J-BJ-BB, Chevillard S, Ory C, Schlumberger M, Dupuy C, et al. Genetic  
547 susceptibility to radiation-related differentiated thyroid cancers: A systematic review of  
548 literature [Internet]. *Endocr. Relat. Cancer BioScientifica Ltd.*; Oct, 2019 page R583–96.  
549 Available from: <https://erc.bioscientifica.com/view/journals/erc/26/10/ERC-19-0321.xml>
- 550 19. Cordina-Duverger E, Leux C, Neri M, Tcheandjieu C, Guizard A-V, Schwartz C, et al.  
551 Hormonal and reproductive risk factors of papillary thyroid cancer: A population-based  
552 case-control study in France. *Cancer Epidemiol* [Internet]. 2017 [cited 2019 May 1];48:78–  
553 84. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1877782117300474>
- 554 20. Xhaard C, Rubino C, Cléro E, Maillard S, Ren Y, Borson-Chazot F, et al. Menstrual and  
555 reproductive factors in the risk of differentiated thyroid carcinoma in young women in  
556 France: A population-based case-control study. *Am J Epidemiol* [Internet]. Narnia; 2014  
557 [cited 2019 May 1];180:1007–17. Available from: [https://academic.oup.com/aje/article-  
558 lookup/doi/10.1093/aje/kwu220](https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwu220)
- 559 21. Chang L, Miller D, Lee C, Melo D, Villoing D, Drozdovitch V, et al. Thyroid Radiation Dose  
560 to Patients from Diagnostic Radiology Procedures over Eight Decades: 1930–2010. *Health*  
561 *Phys* [Internet]. NIH Public Access; 2017 [cited 2019 May 10];113:458–73. Available from:  
562 <http://www.ncbi.nlm.nih.gov/pubmed/28968349>
- 563 22. Amos CI, Dennis J, Wang Z, Byun J, Schumacher FR, Gayther SA, et al. The oncoarray  
564 consortium: A network for understanding the genetic architecture of common cancers.  
565 *Cancer Epidemiol Biomarkers Prev*. American Association for Cancer Research Inc.;  
566 2017;26:126–35.



- 567 23. Li Y, Byun J, Cai G, Xiao X, Han Y, Cornelis O, et al. FastPop: A rapid principal component  
568 derived method to infer intercontinental ancestry using genetic data. *BMC Bioinformatics*  
569 [Internet]. BioMed Central Ltd.; 2016 [cited 2020 Mar 6];17:122. Available from:  
570 <http://www.biomedcentral.com/1471-2105/17/122>
- 571 24. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology:  
572 Tool for the unification of biology. *Nat. Genet.* 2000. page 25–9.
- 573 25. Carbon S, Douglass E, Dunn N, Good B, Harris NL, Lewis SE, et al. The Gene Ontology  
574 Resource: 20 years and still GOing strong. *Nucleic Acids Res.* Oxford University Press;  
575 2019;47:D330–8.
- 576 26. Berrington de Gonzalez A, Daniels RD, Cardis E, Cullings HM, Gilbert E, Hauptmann M, et  
577 al. Epidemiological Studies of Low-Dose Ionizing Radiation and Cancer: Rationale and  
578 Framework for the Monograph and Overview of Eligible Studies. *J Natl Cancer Inst Monogr*  
579 [Internet]. NLM (Medline); 2020 [cited 2021 Feb 4];2020:97–113. Available from:  
580 <https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/32657348/>
- 581 27. Akaike H. Information Theory and an Extension of the Maximum Likelihood Principle BT -  
582 Selected Papers of Hirotugu Akaike. *Second Int Symp Inf Theory.* 1973.
- 583 28. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide  
584 association scans. *Bioinformatics* [Internet]. 2010 [cited 2020 Jan 12];26:2190–1. Available  
585 from: [https://academic.oup.com/bioinformatics/article-](https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btq340)  
586 [lookup/doi/10.1093/bioinformatics/btq340](https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btq340)
- 587 29. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful  
588 Approach to Multiple Testing. *J R Stat Soc Ser B.* Wiley; 1995;57:289–300.
- 589 30. Hunt SE, McLaren W, Gil L. Ensembl variation resources. *Database* [Internet]. 2018 [cited  
590 2020 Mar 9];2018:1–12. Available from: [https://academic.oup.com/database/article-](https://academic.oup.com/database/article-abstract/doi/10.1093/database/bay119/5255129)  
591 [abstract/doi/10.1093/database/bay119/5255129](https://academic.oup.com/database/article-abstract/doi/10.1093/database/bay119/5255129)
- 592 31. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom:  
593 regional visualization of genome-wide association scan results. *Bioinforma Appl NOTE*  
594 [Internet]. 2010 [cited 2020 Mar 9];26:2336–7. Available from: <http://genome.ucsc.edu/>.
- 595 32. Little MP, Lim H, Friesen MC, Preston DL, Doody MM, Sigurdson AJ, et al. Assessment of  
596 thyroid cancer risk associated with radiation dose from personal diagnostic examinations in  
597 a cohort study of US radiologic technologists, followed 1983-2014. *BMJ Open* [Internet].  
598 British Medical Journal Publishing Group; 2018 [cited 2019 May 10];8:e021536. Available  
599 from: <http://www.ncbi.nlm.nih.gov/pubmed/29764888>

- 600 33. Nagarajan P, Onami TM, Rajagopalan S, Kania S, Donnell R, Venkatachalam S. Role of  
601 chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and  
602 tumorigenesis. *Oncogene*. 2009;28:1053–62.
- 603 34. Rajagopalan S, Nepa J, Venkatachalam S. Chromodomain helicase DNA-binding protein 2  
604 affects the repair of X-ray and UV-Induced DNA damage. *Environ Mol Mutagen*.  
605 2012;53:44–50.
- 606 35. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc  
607 enhanced by glycogen synthase kinase-3. *Science* (80- ). 1997;275:1930–3.
- 608 36. Flockhart RJ, Diffey BL, Farr PM, Lloyd J, Reynolds NJ. NFAT regulates induction of COX-  
609 2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure. *FASEB J*  
610 [Internet]. 2008 [cited 2020 Feb 4];22:4218–27. Available from:  
611 <http://www.fasebj.org/doi/10.1096/fj.08-113076>
- 612 37. Glover D, Little JB, Lavin MF, Gueven N. Low dose ionizing radiation-induced activation of  
613 connexin 43 expression. *Int J Radiat Biol*. 2003;79:955–64.
- 614 38. Perotti V, Baldassari P, Molla A, Vegetti C, Bersani I, Maurichi A, et al. NFATc2 is an  
615 intrinsic regulator of melanoma dedifferentiation. *Oncogene*. Nature Publishing Group;  
616 2016;35:2862–72.
- 617 39. Kim GC, Kwon HK, Lee CG, Verma R, Rudra D, Kim T, et al. Upregulation of Ets1  
618 expression by NFATc2 and NFkB1/RELA promotes breast cancer cell invasiveness.  
619 *Oncogenesis*. Nature Publishing Group; 2018;7.
- 620 40. Damani Shah H, Saranath D, Pradhan S. Single nucleotide polymorphisms in transcription  
621 factor genes associated with susceptibility to oral cancer. *J Cell Biochem*. Wiley-Liss Inc.;  
622 2020;121:1050–60.
- 623 41. Lang T, Ding X, Kong L, Zhou X, Zhang Z, Ju H, et al. NFATC2 is a novel therapeutic  
624 target for colorectal cancer stem cells. *Onco Targets Ther*. Dove Medical Press Ltd.;  
625 2018;11:6911–24.
- 626 42. Havre PA, Rice MC, Noe M, Kmiec EB. The human REC2/RAD51B gene acts as a DNA  
627 damage sensor by inducing G1 delay and hypersensitivity to ultraviolet irradiation. *Cancer*  
628 *Res*. American Association for Cancer Research; 1998;58:4733–9.
- 629 43. Takata M, Sasaki MS, Sonoda E, Fukushima T, Morrison C, Albala JS, et al. The Rad51  
630 Paralog Rad51B Promotes Homologous Recombinational Repair. *Mol Cell Biol*. American  
631 Society for Microbiology; 2000;20:6476–82.

- 632 44. Lee PS, Fang J, Jessop L, Myers T, Raj P, Hu N, et al. Rad51b activity and cell cycle  
633 regulation in response to DNA damage in breast cancer cell lines. *Breast Cancer Basic*  
634 *Clin Res* [Internet]. Libertas Academica Ltd.; 2014 [cited 2020 Mar 6];8:135–44. Available  
635 from: <http://journals.sagepub.com/doi/10.4137/BCBCR.S17766>
- 636 45. Pelttari LM, Khan S, Vuorela M, Kiiski JI, Vilske S, Nevanlinna V, et al. RAD51B in Familial  
637 Breast Cancer. Brusgaard K, editor. *PLoS One* [Internet]. Public Library of Science; 2016  
638 [cited 2020 Mar 6];11:e0153788. Available from:  
639 <https://dx.plos.org/10.1371/journal.pone.0153788>
- 640 46. Xu WH, Long JR, Zheng W, Ruan ZX, Cai Q, Cheng JR, et al. Association of thymidylate  
641 synthase gene with endometrial cancer risk in a chinese population. *Cancer Epidemiol*  
642 *Biomarkers Prev* [Internet]. American Association for Cancer Research; 2009 [cited 2020  
643 Nov 3];18:579–84. Available from: <http://www.hapmap.org>
- 644 47. Kelemen L, Earp M, Fridley B, Chenevix-Trench G, Fasching P, Beckmann M, et al.  
645 rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous  
646 Histology. *Int J Mol Sci* [Internet]. MDPI AG; 2018 [cited 2020 Nov 3];19:2473. Available  
647 from: <http://www.mdpi.com/1422-0067/19/9/2473>
- 648 48. Dai Z, Wang S, Zhang W, Yang Y. Elevated Expression of RPA3 Is Involved in Gastric  
649 Cancer Tumorigenesis and Associated with Poor Patient Survival. *Dig Dis Sci* [Internet].  
650 Springer New York LLC; 2017 [cited 2020 Nov 3];62:2369–75. Available from:  
651 <https://link.springer.com/article/10.1007/s10620-017-4696-6>
- 652 49. Lonjou C, Damiola F, Moissonnier M, Durand G, Malakhova I, Masyakin V, et al.  
653 Investigation of DNA repair-related SNPs underlying susceptibility to papillary thyroid  
654 carcinoma reveals MGMT as a novel candidate gene in Belarusian children exposed to  
655 radiation. *BMC Cancer* [Internet]. BMC Cancer; 2017;17:328. Available from:  
656 <http://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3314-5>
- 657 50. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Bentley DR, Chakravarti A, et al. A  
658 global reference for human genetic variation [Internet]. *Nature*. Nature Publishing Group;  
659 2015 [cited 2020 Mar 9]. page 68–74. Available from:  
660 <https://www.nature.com/articles/nature15393>
- 661 51. Heß J, Thomas G, Braselmann H, Bauer V, Bogdanova T, Wienberg J, et al. Gain of  
662 chromosome band 7q11 in papillary thyroid carcinomas of young patients is associated  
663 with exposure to low-dose irradiation. *Proc Natl Acad Sci U S A* [Internet]. *Proc Natl Acad*  
664 *Sci U S A*; 2011 [cited 2020 Dec 30];108:9595–600. Available from: [https://pubmed-ncbi-](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/21606360/)  
665 [nml-nih-gov.proxy.insermbiblio.inist.fr/21606360/](https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/21606360/)

- 666 52. Hallquist A, Jansson P. Self-reported diagnostic X-ray investigation and data from medical  
667 records in case-control studies on thyroid cancer: evidence of recall bias? *Eur J Cancer*  
668 *Prev* [Internet]. 2005 [cited 2020 Feb 18];14:271–6. Available from:  
669 <http://www.ncbi.nlm.nih.gov/pubmed/15901997>
- 670 53. Xhaard C, Dumas A, Souchard V, Ren Y, Borson-Chazot F, Sassolas G, et al. Are dietary  
671 reports in a case-control study on thyroid cancer biased by risk perception of Chernobyl  
672 fallout? *Rev Epidemiol Sante Publique* [Internet]. 2017;65:301–8. Available from:  
673 <https://linkinghub.elsevier.com/retrieve/pii/S0398762017304017>
- 674

*Table 1 References used for thyroid radiation dose estimates per diagnostic procedure type*

Exams types	Doses in mGy				References
	Childhood exposure age < 2	Childhood exposure age > 2 years and adulthood exams			
		Before 1980	1980-1989	1990 and after	
<b>Conventional Radiography</b>					
Skull	- §	3.6	3.6	0.42	Chang et al. 2017
Dental (panoramic)	- §	0.56	0.07	0.02	Chang et al. 2017
Paranasal sinuses	- §	0.02	0.04	0.04	Chang et al. 2017
Intravenous urography	0.38*	0.38	0.21	0.21	Inskip et al. 1995
Chest	0.13	0.16	0.31	0.19	Almén and Mattsson 1995 / Chang et al. 2017
Spine	2.8*	2.8	4.5	0.99	Chang et al. 2017
<b>CT Scan</b>					
Skull	3	0.43	0.49	0.64	Lee et al. 2007 / Chang et al. 2017
Chest	5.9	15	20.5	22	Mabille et al. 2008 / Chang et al. 2017
Spine	13.5	17	24	25.5	Mabille et al. 2008 / Chang et al. 2017
Abdomen	0.17	0.28	0.38	0.41	Mabille et al. 2008 / Chang et al. 2017
<b>Nuclear medicine</b>					
Bone scan	1.1*	1.1	0.96	1.1	Chang et al. 2017
Brain scan	- §	1.3	3.6	9	Chang et al. 2017
Lung scan (perfusion/ventilation)	- §	0.2	0.25	0.25	Chang et al. 2017
Heart scan	- §	11	17	12	Chang et al. 2017
Liver scan	- §	0.15	0.15	0.15	Chang et al. 2017
Renal scan	- §	0.17	0.31	0.17	Chang et al. 2017

§: No exposed subject at this age

\*: No available data for children, adult data used

*Table 2 Clinical and demographic description of the population included in DTC risk in relation to thyroid radiation doses analysis and genetic analysis*

	Whole population		The population included in the genetic analysis	
	Cases (n = 1393)	Controls (n = 1580)	Cases (n = 1072)	Controls (n = 1188)
<b>Gender (%)</b>				
Men	300 (21.5)	398 (25.2)	228 (21.3)	302 (25.4)
Women	1093 (78.5)	1182 (74.8)	844 (78.7)	886 (74.6)
<b>Age at diagnosis/reference year (years)</b>				
Mean	37.58	37.21	37.4 (15.0)	37.6 (15.2)
Median [Min, Max]	32.0 [9.00, 83.0]	32.0 [9.00, 83.0]	32.0 [11.0, 83.0]	32.0 [9.00, 80.0]
<b>Smoking status (%)</b>				
Non-smoker	739 (53.1)	768 (48.6)	232 (52.4)	271 (50.9)
Former smoker	304 (21.8)	306 (19.4)	140 (31.6)	149 (28.0)
Smoker	350 (25.1)	506 (32.0)	71 (16.0)	112 (21.1)
<b>Alcohol consumption (Number of alcohol glasses per week) (%)</b>				
No consumption	778 (55.9)	763 (48.3)	582 (54.3)	559 (47.1)
Less than 10	504 (36.2)	673 (42.6)	403 (37.6)	521 (43.9)
More than 10	110 (7.9)	144 (9.1)	87 (8.1)	108 (9.1)
<b>BMI (Kg/m<sup>2</sup>)</b>				
Mean (SD)	24.6 (5.21)	24.1 (4.88)	24.7 (5.36)	24.2 (4.89)
Median [Min, Max]	23.5 [11.0, 51.8]	23.1 [13.4, 49.1]	23.6 [11.0, 51.8]	23.1 [13.4, 48.7]
<b>Goitre history (%)</b>				
No	899 (64.5)	1468 (92.9)	695 (64.8)	1102 (92.8)
Yes	494 (35.5)	112 (7.1)	377 (35.2)	86 (7.2)
<b>Thyroid cancer family history (%)</b>				
No	1542 (97.6)	1322 (94.9)	1023 (95.4)	1158 (97.5)
Yes	38 (2.4)	71 (5.1)	49 (4.6)	30 (2.5)
<b>Radiotherapy history (%)</b>				
No	1558 (98.6)	1354 (97.2)	1043 (97.3)	1168 (98.3)
Yes	29 (2.8)	22 (1.3)	19 (1.7)	20 (1.6)
<b>Educational level (%)</b>				
Bachelor's degree or higher	765 (54.9)	982 (62.2)	618 (57.6)	743 (62.5)
Secondary school	418 (30.0)	406 (25.7)	315 (29.4)	311 (26.2)
Primary school level	210 (15.1)	192 (12.2)	139 (13.0)	134 (11.3)
<b>Childhood thyroid radiation doses in mGy (%)</b>				
0	1021 (73.3)	1161 (73.5)	777 (72.5)	876 (73.7)
]0,1]	112 (8.0)	147 (9.3)	89 (8.3)	104 (8.8)
]1,5]	139 (10.0)	150 (9.5)	116 (10.8)	113 (9.5)
]5,10]	25 (1.8)	45 (2.8)	18 (1.7)	36 (3.0)
]10,20]	49 (3.5)	57 (3.6)	35 (3.3)	42 (3.5)
>20	46 (3.3)	20 (1.3)	37 (3.5)	17 (1.4)
Mean (sd)	2.79 (10.3)	1.98 (6.18)	2.89 (11.1)	2.11 (6.62)
Median [Min, Max]	0 [0, 194]	0 [0, 80.9]	0 [0, 194]	0 [0, 80.9]
<b>Adulthood thyroid radiation doses in mGy (%)</b>				
0	669 (48.1)	797 (50.4)	523 (48.8)	591 (49.7)
]0,1]	247 (17.7)	283 (17.9)	187 (17.4)	220 (18.5)
]1,5]	245 (17.6)	262 (16.6)	182 (17.0)	193 (16.2)
]5,10]	59 (4.2)	61 (3.9)	46 (4.3)	46 (3.9)
]10,20]	53 (3.8)	43 (2.7)	44 (4.1)	35 (2.9)
>20	119 (8.5)	134 (8.5)	90 (8.4)	103 (8.7)
Mean (sd)	5.63 (17.3)	5.50 (17.9)	5.28 (16.6)	5.54 (17.2)
Median [Min, Max]	0 [0, 245]	0.02 [0, 262]	0.02 [0, 245]	0.02 [0, 157]
<b>Number of children (%)</b>				
0 (and men)	666 (47.8)	829 (52.5)	514 (47.9)	622 (52.4)
1-3	648 (46.6)	529 (43.8)	542 (50.6)	542 (45.6)
4-6	67 (4.8)	44 (3.4)	10 (0.9)	20 (1.7)
>6	11 (0.4)	4 (0.3)	6 (0.6)	4 (0.3)
<b>Study</b>				
Young-Thyr (%)	805 (57.8)	876 (55.4)	629 (58.7)	656 (55.2)
Cathy (%)	587 (42.2)	704 (44.6)	443 (41.3)	532 (44.8)
<b>Thyroid cancer histology (%)</b>				
Follicular	140 (10.1)		109 (10.2)	
Papillary	1243 (89.2)		955 (89.1)	
Missing	10 (0.7)		8 (0.7)	
<b>Thyroid cancer size in mm (%)</b>				
< 10	431 (31.0)		341 (31.8)	
> 10	957 (68.8)		729 (68.0)	
Missing	4 (0.28)		2 (0.2)	

*Table 3 Number of subjects by age and exam type*

	Cases n (%) having at least 1 listed exam		Controls n (%) having at least 1 listed exam	
	<20 years	>=20 years	<20 years	>=20 years
Conventional radiography				
Skull	89 (6.4)	93 (6.7)	94 (5.9)	82 (5.2)
Sinus	67 (4.8)	124 (8.9)	77 (4.9)	133 (8.4)
Dental	416 (29.9)	260 (18.7)	555 (35.1)	309 (19.6)
Spine	180 (12.9)	277 (19.9)	199 (12.6)	296 (18.7)
Chest	159 (11.4)	451 (32.4)	198 (12.5)	465 (29.4)
Intravenous urography	27 (1.9)	94 (6.7)	31 (2.0)	74 (4.7)
CT scan				
Abdomen	7 (0.5)	47 (3.4)	2 (0.1)	33 (2.1)
Chest	8 (0.6)	46 (3.3)	0 (0)	33 (2.1)
Skull	53 (3.8)	137 (9.8)	47 (3.0)	117 (7.4)
Spine	31 (2.22)	122 (8.75)	29 (1.83)	160(10.12)
Nuclear medicine				
Cerebral	1 (0.1)	3 (0.2)	0 (0)	9 (0.6)
Heart	1 (0.1)	2 (0.1)	1 (0.1)	7 (0.4)
Lung	1 (0.1)	3 (0.2)	0 (0)	7 (0.4)
Bones	8 (0.6)	43 (3.1)	6 (0.4)	52 (3.3)
Hepatic	0 (0)	2 (0.1)	0 (0)	2 (0.1)
Renal	4 (0.3)	5 (0.4)	5 (0.3)	13 (0.8)

Table 4: Dose-response analysis for thyroid radiation dose: – Whole population and subgroups

	Whole population: Adjusted analysis				Only micro-carcinomas cases (431 cases and 1580 controls)				Excluding micro-carcinomas cases (962 cases and 1580 controls)			
	Coefficient (95%CI) for 1 mGy	OR <sup>a</sup> (95%CI) at 1 mGy	Deviance	P-value	Coefficient (95%CI) for 1 mGy	OR <sup>a</sup> (95%CI) at 1 mGy	Deviance	P-value	Coefficient (95%CI) for 1 mGy	OR <sup>a</sup> (95%CI) at 1 mGy	Deviance	P-value
<b>No radiation dose-</b>			3966.7				2370.9				3029.4	
<b>The radiation dose received during childhood</b>												
Linear	0.017 (0.00060, 0.035)	1.02 (1.00, 1.03)	3959.5	0.007	0.024 (-0.0024, 0.051)	1.02 (1.00, 1.05)	2363.6	0.008	0.015 (-0.0041, 0.035)	1.01 (0.99, 1.04)	3025.2	0.04
Quadratic	0.00053 (-0.00047-0.0011)	1 (1.00, 1.00)	3957.9	0.003	0.00078 (-0.00011, 0.0017)	1 (1.00, 1.00)	2361.8	0.003	0.00048 (-0.00015, 0.00079)	1 (1.00, 1.00)	3024	0.02
Exponential	0.022 (0.0081-0.036)	1.01 (1.01, 1.04)	3058.4	0.004	0.026 (0.010, 0.042)	1.03 (1.01, 1.04)	2362	0.003	0.021 (0.0049-0.037)	1.02 (0.99, 1.05)	3024.6	0.03
<b>The radiation dose received during adulthood</b>												
Linear	8.7 10 <sup>-5</sup> (-6.0.10 <sup>-4</sup> , 7.7.10 <sup>-4</sup> )	1 (1.00, 1.00)	3966.7	>0.9	-8.6 10 <sup>-4</sup> (-5.8.10 <sup>-3</sup> , 4.0.10 <sup>-3</sup> )	1 (0.99, 1.01)	2370.8	> 0.9	-2.7 10 <sup>-5</sup> (-5.4 10 <sup>-3</sup> , 5.3.10 <sup>-3</sup> )	1 (1.0, 1.00)	3029.4	> 0.9
Quadratic	-9.1 10 <sup>-6</sup> (-2.610 <sup>-5</sup> , 7.4 10 <sup>-6</sup> )	1 (1.00, 1.00)	3966.2	>0.5	-6.0 10 <sup>-8</sup> (-3.1 10 <sup>-5</sup> , 1.9 10 <sup>-5</sup> )	1 (1.00, 1.00)	2370.7	> 0.9	-1.5 10 <sup>-3</sup> (-1.5 10 <sup>-5</sup> , 1.5 10 <sup>-5</sup> )	1 (1.00, 1.00)	3028.5	0.4
Exponential	1.2 10 <sup>-4</sup> (-0.0089, 0.0091)	1 (0.99, 1.01)	3966.7	>0.9	-1.6 10 <sup>-3</sup> (-0.014, 0.011)	1 (0.99, 1.01)	2370.8	> 0.9	-3.4 10 <sup>-3</sup> (-0.011, 0.011)	0.99 (0.99, 1.01)	3029.4	> 0.9

<sup>a</sup> Stratified on age, sex, and study, and adjusted on thyroid cancer family history, radiotherapy history, BMI, height, smoking habits, and number of pregnancies



Table 5 SNPs with the lowest p-values associated with DTC risk in the meta-analysis among all DTC types cases (A), among only papillary DTC cases (B), macrocarcinoma cases (C), and microcarcinoma cases (D)

A/ SNPs with lowest p-values associated with DTC risk in the meta-analysis including all histological types												
SNP	Locus	RA	EA	EAF	Gene	Young-Thyr		CATHY		Meta-analysis		
						OR <sup>a</sup>	P-value	OR <sup>a</sup>	P-value	OR <sup>a</sup>	P-value	FDR p-value
rs12702628	7p21.3	A	G	0.4	RPA3	1.25	1.03 10 <sup>-2</sup>	1.22	4.37 10 <sup>-2</sup>	1.24	1.12 10 <sup>-03</sup>	0.02
rs7164173	15q26.1	G	T	0.1	CHD2	0.7	1.05 10 <sup>-3</sup>	0.69	1.06 10 <sup>-2</sup>	0.68	9.26 10 <sup>-05</sup>	0.004
rs1059394	18p11.32	C	T	0.3	ENOSF1/THYS	1.34	2.91 10 <sup>-3</sup>	1.19	8.97 10 <sup>-2</sup>	1.3	7.81 10 <sup>-04</sup>	0.01
rs699517	18p11.32	C	T	0.3	ENOSF1/THYS	1.34	2.91 10 <sup>-3</sup>	1.19	8.97 10 <sup>-2</sup>	1.3	7.81 10 <sup>-04</sup>	0.01
rs6067822	20q13.2	G	T	0.3	NFATc2	0.64	1.6 10 <sup>-3</sup>	0.7	1.13 10 <sup>-3</sup>	0.64	5.79 10 <sup>-05</sup>	0.005
B/ SNPs with lowest p-values associated with papillary thyroid carcinoma risk in the meta-analysis (563 cases from Young-Thyr and 392 cases from CATHY)												
SNP	Locus	RA	EA	EAF	Gene	Young-Thyr		CATHY		Meta-analysis		
						OR <sup>a</sup>	P-value	OR <sup>a</sup>	P-value	OR <sup>a</sup>	P-value	FDR p-value
rs1950764	14q24.1	G	A	0.2	RAD51B	0.56	2.87 10 <sup>-03</sup>	0.66	7.27 10 <sup>-02</sup>	0.6	6.08 10 <sup>-04</sup>	0.01
rs1290997	14q24.1	G	T	0.2	RAD51B	0.77	2.01 10 <sup>-03</sup>	0.7	7.18 10 <sup>-02</sup>	0.74	4.36 10 <sup>-04</sup>	0.01
rs7164173	15q26.1	G	T	0.3	CHD2	0.69	3.24 10 <sup>-03</sup>	0.68	1.02 10 <sup>-02</sup>	0.68	9.33 10 <sup>-05</sup>	0.009
rs77971457	20q13.2	G	T	0.1	NFATc2	1.44	1.09 10 <sup>-03</sup>	1.47	1.76 10 <sup>-02</sup>	1.45	5.06 10 <sup>-04</sup>	0.01
rs6067822	20q13.2	G	T	0.3	NFATc2	0.81	3.47 10 <sup>-03</sup>	0.72	4.63 10 <sup>-02</sup>	0.77	5.59 10 <sup>-04</sup>	0.01
C/ SNPs with lowest p-values associated with large thyroid carcinoma (>10mm) risk in the meta-analysis (501 cases from Young-Thyr and 237 cases from CATHY)												
SNP	Locus	RA	EA	EAF	Gene	Young-Thyr		CATHY		Meta-analysis		
						OR <sup>a</sup>	P-value	OR <sup>a</sup>	P-value	OR <sup>a</sup>	P-value	FDR p-value
rs72625242	2q31.1	C	T	0.22	MLK7-AS1	1.927	6.27 10 <sup>-3</sup>	0.9934	1	1.927	6.25 10 <sup>-3</sup>	0.004
rs17619600	2q37.1	T	C	0.15	PMSD1	1.855	1.20 10 <sup>-3</sup>	1.01	0.9999	1.855	1.20 10 <sup>-3</sup>	0.004
rs7578070	2p24.2	A	G	0.41	SMC6	1.538	1.86 10 <sup>-3</sup>	1.03	0.9998	1.538	1.86 10 <sup>-3</sup>	0.004
rs16861406	2q31.1	A	G	0.21	MLK7-AS1	1.912	2.56 10 <sup>-3</sup>	1.009	1	1.912	2.56 10 <sup>-3</sup>	0.005
rs5023821	10q26.2	T	C	0.25	C10orf90	0.6249	1.14 10 <sup>-3</sup>	1.026	0.9998	0.6249	1.14 10 <sup>-3</sup>	0.004
D/ SNPs with lowest p-values associated with small thyroid carcinoma (<10mm) risk in the meta-analysis (128 cases from Young-Thyr and 206 cases from CATHY)												
SNP	Locus	RA	EA	EAF	Gene	Young-Thyr		CATHY		Meta-analysis		
						OR <sup>a</sup>	P-value	OR <sup>a</sup>	P-value	OR <sup>a</sup>	P-value	FDR p-value
rs75361806	2q31.1	A	G	0.05	TLK1	25.55	1.12 10 <sup>-2</sup>	1.02	1	25.5494	1.12 10 <sup>-2</sup>	0.03
rs73234091	20p12.1	T	C	0.05	MACROD2	30.89	6.99 10 <sup>-3</sup>	1.007	1	30.8891	6.99 10 <sup>-3</sup>	0.03
rs17757541	18q21.33	C	G	0.06	BCL2	7.188	1.22 10 <sup>-2</sup>	1.005	1	7.1877	1.12 10 <sup>-2</sup>	0.01
rs116851051	20p12.1	T	C	0.1	MACROD2	28.39	1.12 10 <sup>-2</sup>	0.9935	1	28.3897	1.12 10 <sup>-2</sup>	0.035
rs2327965	20p12.1	A	G	0.05	MACROD2	27.11	1.12 10 <sup>-2</sup>	1.016	1	27.1096	1.12 10 <sup>-2</sup>	0.03

RA=Reference allele

EA= Effect allele

EAF= Effect allele frequency

<sup>a</sup>: Adjusted on age, sex, childhood IR thyroid doses, thyroid cancer family history, radiotherapy history, goiter history, BMI, height, educational level, smoking status, number of pregnancies, and three first genetic components

*Table 6 Five SNPs with the lowest p-values in SNPs - diagnostic radiation thyroid doses interaction term from the meta-analysis*

SNP	Locus	Reference allele	Effect allele	EAF	Gene	Young-Thyr		CATHY		Meta-analysis		
						OR <sup>a</sup>	P value	OR <sup>a</sup>	P value	OR	P value	FDR correction
rs10779613	1q41	T	C	0.4	<i>SMYD2</i>	0.60	1.19 10 <sup>-03</sup>	0.94	6.08 10 <sup>-01</sup>	0.80	5.42 10 <sup>-03</sup>	0.1
rs17514740	7p11.2	G	C	0.4	<i>EGFR</i>	0.71	9.39 10 <sup>-03</sup>	1.19	1.84 10 <sup>-01</sup>	1.30	4.64 10 <sup>-03</sup>	0.1
rs7068306	10q26.3	C	G	0.3	<i>MGMT</i>	0.63	1.91 10 <sup>-03</sup>	0.70	5.85 10 <sup>-02</sup>	0.65	3.40 10 <sup>-04</sup>	0.03
rs10402248	19p13.3	C	T	0.4	<i>MUM1</i>	0.65	4.79 10 <sup>-03</sup>	0.85	2.54 10 <sup>-01</sup>	0.75	4.03 10 <sup>-03</sup>	0.1
rs6066138	20q13.12	G	A	0.2	<i>EYA2</i>	1.52	9.73 10 <sup>-03</sup>	1.22	9.01 10 <sup>-02</sup>	1.32	2.20 10 <sup>-03</sup>	0.1

EAF= Effect allele frequency

OR = Odds Ratio for the interaction between Effect Allele and radiation dose, considered as a continuous variable in an exponential dose-response model

<sup>a</sup>: Adjusted on age, sex, thyroid cancer family history, radiotherapy history, goiter history, BMI, height, educational level, smoking status, number of pregnancies, and three first genetic components

# Cancer Epidemiology, Biomarkers & Prevention

**AACR** American Association  
for Cancer Research

## Role of DNA repair variants and diagnostic radiology exams in differentiated thyroid cancer risk: a pooled-analysis of two case-control studies

Monia Zidane, Therese Truong, Fabienne Lesueur, et al.

*Cancer Epidemiol Biomarkers Prev* Published OnlineFirst April 7, 2021.

<b>Updated version</b>	Access the most recent version of this article at: doi: <a href="https://doi.org/10.1158/1055-9965.EPI-20-1142">10.1158/1055-9965.EPI-20-1142</a>
<b>Supplementary Material</b>	Access the most recent supplemental material at: <a href="http://cebp.aacrjournals.org/content/suppl/2021/04/03/1055-9965.EPI-20-1142.DC1">http://cebp.aacrjournals.org/content/suppl/2021/04/03/1055-9965.EPI-20-1142.DC1</a>
<b>Author Manuscript</b>	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

<b>E-mail alerts</b>	<a href="#">Sign up to receive free email-alerts</a> related to this article or journal.
<b>Reprints and Subscriptions</b>	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a> .
<b>Permissions</b>	To request permission to re-use all or part of this article, use this link <a href="http://cebp.aacrjournals.org/content/early/2021/04/06/1055-9965.EPI-20-1142">http://cebp.aacrjournals.org/content/early/2021/04/06/1055-9965.EPI-20-1142</a> . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.